PolicyRSSToday
President Trump signed an executive order on April 18 directing the federal government to speed up access to treatments for serious mental illness, including conditions that are hard to treat. This means the FDA and other health agencies will work faster to get new mental health treatments to patients who need them.
WHY IT MATTERSPatients with treatment-resistant mental illness conditions may gain faster access to new therapies through streamlined FDA review processes and accelerated approval pathways.
AdvocacyRSS2 days ago
A patient with MS shares their personal experience of why starting treatment quickly with the most powerful available medications is worth it to them. They believe the benefits of aggressive, early treatment outweigh the potential side effects. This is one patient's perspective on MS treatment strategy.
WHY IT MATTERSThis patient perspective highlights the real-world decision-making that people with MS face when choosing between starting strong treatments early versus waiting, which can help other newly diagnosed patients think through their own treatment conversations.
AdvocacyRSS2 days ago
A parent shares their experience with their son's delayed diagnosis of thymidine kinase 2 deficiency (TK2d), a rare genetic disorder affecting how the body uses certain building blocks for DNA. The article highlights how early genetic testing could have identified the condition sooner and made a significant difference in the child's care and outcomes. Early testing is important because it allows doctors to start treatment and management strategies before serious complications develop.
WHY IT MATTERSParents of children with unexplained developmental delays or muscle weakness can use this story to advocate for early genetic testing with their doctors, potentially catching TK2d before irreversible damage occurs.
AdvocacyRSS2 days ago
This article uses the excitement of NASA's Artemis II space mission as inspiration to encourage big dreams about finding a cure for pulmonary hypertension, a serious lung disease that affects blood vessels. The author draws a parallel between humanity's ability to reach for the stars and the hope that patients with pulmonary hypertension should have for breakthrough treatments. The piece is motivational rather than reporting on specific medical news or research developments.
WHY IT MATTERSThis article may resonate emotionally with pulmonary hypertension patients by framing their disease journey within a larger narrative of human achievement and possibility, though it does not announce any new treatments, trials, or clinical developments.
AdvocacyRSS2 days ago
A patient with von Willebrand disease shares how much they depend on Humate-P, a medication made from donated plasma. The article highlights how plasma donors' generosity directly impacts the lives of people who need plasma-derived treatments to stay healthy and safe.
WHY IT MATTERSPatients relying on plasma-derived therapies like Humate-P depend on a consistent supply of donated plasma — understanding this connection may inspire more people to become plasma donors and help secure treatment availability.
AdvocacyRSS2 days ago
Three organizations that work with facioscapulohumeral muscular dystrophy (FSHD) patients are joining together to make clinical trials better. FSHD is a rare muscle disease that causes weakness in the face, shoulders, and upper arms. This partnership wants to improve how these trials are designed so they can test new treatments more effectively.
WHY IT MATTERSBetter-designed clinical trials mean faster progress toward treatments for FSHD, and patient input through the FSHD Society ensures trials are structured in ways that actually work for people living with the disease.
AdvocacyRSS2 days ago
A patient-led nonprofit called The Speak Foundation has created a network of specialized clinics called LGMD Centers of Excellence to help people with limb-girdle muscular dystrophy (LGMD), a rare muscle disease. This new network aims to solve a major problem: patients with LGMD have had trouble getting consistent care and doctors have struggled to develop new treatments because the patient population is very small and spread out.
WHY IT MATTERSThis coordinated clinic network could help LGMD patients access specialized care in one place and speed up the development of new treatments by making it easier for researchers to find and study patients.